Treatment Duration in Patients With Transplant-Ineligible NDMM
Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.
EP: 1.Coming Soon: Advances in Multiple Myeloma: Insights from Experts at the Moffit Cancer Center
EP: 2.Transplant-Eligible NDMM: Overview of Available Induction Therapies
EP: 3.Selection of Induction Therapy in Patients With Transplant-Eligible NDMM
EP: 4.Patient Profile 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 5.Selecting First-Line Therapy for Patients With Transplant-Ineligible NDMM
EP: 6.Transplant-Ineligible NDMM: Optimizing Therapy for Frailer Patients
Now Viewing
EP: 7.Treatment Duration in Patients With Transplant-Ineligible NDMM
EP: 8.Patient Profile 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 9.Relapsed/Refractory Multiple Myeloma: Overview of Treatment Options
EP: 10.Sequencing Therapies in Relapsed/Refractory Multiple Myeloma
EP: 11.Bispecifics in the Treatment of Multiple Myeloma: Teclistamab
EP: 12.BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma
EP: 13.Non-BCMA Targeting Therapies in Multiple Myeloma
EP: 14.Experts Discuss SOC for Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 15.Bispecifics-Based Combination Therapy in Multiple Myeloma
EP: 16.CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
EP: 17.Patient Profile 3: Patient With MM Progressing After Several Prior Therapies
EP: 18.Multiple Myeloma: Unmet Needs and Future Perspectives
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
